RxDoctor Payments Data

Eric Johnson, MD

Hematology & Oncology · Salt Lake City, UTNPI 1649665399

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (48.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. BTG International Inc. accounts for 93.9% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $13,921, more than ten times the $60 reported in 2019.

$14,761in general payments, 2019–2025

Across 34 payments — averaging $434.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • BTG International Inc.$14K
  • Stryker$305
  • Astellas Pharma US Inc$170
  • Viiv Healthcare Company$132
  • Sanofi$103
  • Teva Pharmaceuticals USA, Inc.$48
  • plus $148 from 6 others

What the payments were for

  • Consulting fees$7,18049%
  • Travel & lodging$6,28143%
  • Food & beverage$1,1047%
  • Education$1961%

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,761 in reported general payments places this provider in the 70th percentile of 77 hematology & oncology providers in Utah.

See all hematology & oncology providers in Utah

Medicare billing

Part B allowed, 2024
$119,790
Medicare patients
230
Services billed
1,329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate49$782,887
RevlimidLenalidomide31$621,506
ImbruvicaIbrutinib15$251,315
BrukinsaZanubrutinib12$179,526
LonsurfTrifluridine/Tipiracil Hcl13$173,967
ZykadiaCeritinib13$167,400
EliquisApixaban59$49,945
Abiraterone Acetate29$14,485
Anastrozole88$1,649
Letrozole91$1,524
Oxycodone Hcl52$759
Dexamethasone43$746
Prochlorperazine Maleate41$478
Lidocaine-PrilocaineLidocaine/Prilocaine36$478
Gabapentin29$453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$40$782,88749 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$48$42557 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 77 hematology & oncology providers in Utah.

Other hematology & oncology in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →